Tier 2 — strong

A randomized, controlled clinical trial demonstrates improved owner-assessed cognitive function in senior dogs receiving a senolytic and NAD+ precursor combination

Katherine E. Simon, Katharine Russell, Alejandra Mondino, Chin-Chieh Yang, Beth C. Case, Zachary Anderson, Christine Whitley, Emily Griffith, Margaret E. Gruen, Natasha J. Olby
Scientific Reports 2024 14:12399

Bibliography

PubMed
PMID 38811634
PubMed Central
PMC11137034
DOI
10.1038/s41598-024-63031-w
Funding
Animal Bioscience, Boston MA; authors reported funder had no role in data acquisition, analysis or presentation.
Competing interests
Authors declared no competing interests. Proprietary product constituent identity was not established to include fisetin.

Study snapshot

DesignRandomized placebo-controlled three-arm blinded clinical trial.
ModelSenior companion dogs with mild to moderate cognitive impairment.
Sample70 dogs enrolled; 59 evaluable at three-month primary endpoint; 51 at six months.
InterventionProprietary LY-D6/2 senolytic and NAD+ precursor combination; no evidence it contains fisetin.
DurationThree-month primary and six-month secondary assessment.
EndpointsOwner-rated Canine Cognitive Dysfunction Rating; Physical activity monitors; In-house cognition tests; Adverse events

What the study showed, in plain terms

Seventy older dogs joined a controlled trial of a proprietary senolytic–NAD+ precursor product. At three months, owner-rated cognition differed between groups (p=0.02), but in-house cognitive testing and objective activity measures did not show significant differences. The trial does not establish efficacy, safety or dosing for standalone fisetin in dogs or cats.

Key findings

Owner-rated cognitive measure differed between groups (p=0.02); objective activity and in-house cognition did not.

Adverse events occurred similarly across groups.

What this study can and cannot tell us

Proprietary combination with no basis to identify the senolytic as fisetin.

Mixed subjective and objective outcomes; not a study of fisetin monotherapy or feline dosing.

Citation network

Articles citing this research paper

1 article

Biohack Blueprint analyses that reference this study in their evidence base.

Editorial review

Reviewed by the Biohack Blueprint research team

Last verified

Dr. Khaled Mahmoud, MBBChCritical Care Medicine, Longevity Science & Editorial Direction Dr. Amr Yasser, PhDCardiometabolic, Musculoskeletal, Gut & Bioavailability Dr. Abdulla Mostafa, PhDCellular Senescence, Neurological, Mitochondrial & Brain-Ageing Biology